Biomarkers for Diagnosis of Heart Failure in Diabetes
Heart failure (HF) is a frequent complication of both type 1 diabetes and type 2 diabetes. Early identification and initiation of treatment to delay or prevent progression of preclinical to clinical HF are important public health objectives. Natriuretic peptides, BNP and NT-proBNP are recognized as surrogates for intracardiac volumes and filling pressures. They are currently considered as the best biomarkers for prevention, diagnosis, and prognostications of HF. These peptides indicate cardiac myocyte stretch and wall stress due to volume overload, which are mechanistically linked to HF.
Diabetes Technology Society is bringing together a panel of clinician experts in diabetology, cardiology, and clinical chemistry to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF). These people are, by definition, at risk for HF. This webinar will review features of heart failure in people with diabetes.
Date: Wednesday, September 20, 2023
Time: 9:00 - 10:30 AM Pacific / 12:00 - 1:30 PM Eastern
Supported by a grant from Roche Diagnostics